New transducers may simplify treatment of prostate cancer

July 02, 2001

CHAMPAIGN, Ill. -- Researchers at the University of Illinois are developing transducers to improve the performance of ultrasound surgical beams used to treat both prostate cancer - the second leading cause of cancer death in American men - and the often painful but benign enlargement of the prostate. "Anatomical constraints on the size and shape of the probe make the design particularly challenging," said Leon Frizzell, a UI professor of electrical and computer engineering and a researcher in the university's Beckman Institute for Advanced Science and Technology. "We are working with Focus Surgery Inc. in Indianapolis to develop and test these novel transducers."

In the current design, a piezoelectric transducer - mounted in a probe that is inserted through the patient's rectum - generates a high-intensity beam of ultrasound. As the sound waves propagate through the body, some of the energy is absorbed and converted into heat, which destroys the tissue. The simple, hemispherical transducer now in use has a fixed focus, like a mirror in a telescope, Frizzell said. The probe is mounted on a rod that can be rotated from side to side and moved back and forth. To penetrate the prostate at different depths, however, the probe must be removed and the transducer replaced, which is both inconvenient and time-consuming.

"What's needed is a more versatile, phased-array transducer system," Frizzell said. "By splitting the transducer into separate elements, and then adjusting the timing of signals applied to those elements, the focus of the array can be moved electronically, without the need of mechanical scanning." To maximize the performance of such an array, Frizzell and graduate student Joseph Tan performed computational studies of various transducer configurations, including a truncated spherical annular array, a truncated spherical shell linear array and a "flat" cylindrical array.

"The spherical arrays performed well when electronically steered along the array axis, but they performed poorly when steered laterally along the length of the prostate," Frizzell said. "The flat cylindrical array performed much better along the length of the prostate, but poorly along the axis." However, a compromise design - a curved cylindrical array - showed acceptable performance for steering both in depth and along the length of the prostate. While this design would permit more flexible electronic scanning of the prostate, the array would be extremely difficult to fabricate.

"At present, a prototype of our best spherical, annular phased-array has been built and is undergoing tests," Frizzell said. "Although you still have to rotate the probe and slide it back and forth, you don't have to remove the transducer to change the focus. That's definitely a step in the right direction."
Collaborators on the project include Narendra Sanghvi, Ralf Seip and Jimmy Wu at Focus Surgery and Jeffrey Kouzmanoff at Labthermics Technologies in Champaign. The researchers describe their phased-array transducers in the June issue of the Journal of the Acoustical Society of America.

University of Illinois at Urbana-Champaign

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to